Project Grant R01AI187580
Award Date 8/13/25
Completion Date 7/31/29
Dollars Obligated $3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Oregon, USA
Similar Awards
- This $525,095 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify novel cellular determinants of human cytomegalovirus (HCMV) infection. The University of Rochester, the primary awardee, aims to: Elucidate the mechanisms through which the cellular factor JUNB can restrict HCMV infection. JUNB is a stress-induced transcription factor that regulates...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $682,879 to The Medical College of Wisconsin, Inc. to conduct research on the impacts of human cytomegalovirus (HCMV) infection on human neural tissue development. The project aims to (1) define the transcriptional and cellular disruptions to developing human neural cells caused by HCMV infection, (2) determine...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), awarded a $762,983 Project Grant to The Medical College of Wisconsin, Inc. (MCW) to support research focused on "Discovery and Development of Novel HCMV Inhibitors". The goal of this project is to develop a new class of inhibitors that act through a novel viral target, the helicase-primase (H/P) complex, to address the limited...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,047,991 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Rector & Visitors of the University of Virginia. The grant, awarded on September 12, 2025, will fund research to investigate the molecular basis for paired receptor signaling in antiviral natural killer (NK) cells during murine cytomegalovirus (MCMV) infection. The research aims to delineate how NK cell receptor...
- The National Institute of Allergy and Infectious Diseases (NIAID), through its Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $1,135,986 Project Grant to Northwestern University. The grant, effective January 1, 2025, aims to identify cellular and molecular targets for developing tissue/cell-specific strategies to prevent cytomegalovirus (CMV) reactivation and improve outcomes in kidney transplant recipients. The research will investigate the role of...
- This $832,910 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify immune factors associated with risk of cytomegalovirus (CMV) disease in orthotopic liver transplant recipients. The University of Washington is the primary awardee, with the goal of developing a clinically useful measure of CMV disease risk to guide prevention efforts. The research focuses on...
- This $306,704 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to identify and characterize a novel, pro-viral function of the cellular protein Stem-Loop Binding Protein (SLBP) that promotes the infectivity of Human Cytomegalovirus (HCMV). The key objectives are to determine the SLBP function required to enhance HCMV infectivity,...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $683,995.00 to fund research to develop novel therapeutics targeting human cytomegalovirus (CMV) infections. The research focuses on characterizing the mechanism of action and optimizing a series of N-arylpyrimidinamine (NAPA) compounds that demonstrated potent anti-CMV activity in a high-throughput screening assay....
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $232,415 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis. The goal of this 2-year award, with a period of performance from November 2024 to October 2026, is to develop a highly potent monoclonal antibody that can neutralize the cytomegalovirus (CMV)-encoded interleukin-10 (IL-10) protein, in order to prevent primary CMV infection and reduce the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $683,927 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai (ISMMS) to develop and characterize broadly neutralizing human monoclonal antibodies (mAbs) as potential therapeutics to inhibit human cytomegalovirus (CMV) infection and dissemination. The key objectives of this 1-year project are to: 1) identify neutralizing CMV mAbs targeting...